S-ICD Electrode Registry

Sponsor
Universitätsklinikum Köln (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05713708
Collaborator
(none)
1,000
1
7.1
141.6

Study Details

Study Description

Brief Summary

The S-ICD is established in the prevention of sudden cardiac death, but recently a defect of the electrode's Sense-B component was reported in some patients. This lead to inadequate shocks due to noise. The cause and incidence of this defect are unknown. The manufacturer issued a warning regarding this defect and a possible premature depletion of the battery in some device. Independent data on the incidence of these issues is limited. Further data is needed to better understand the risk of these complications.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The S-ICD therapy is an established treatment for primary and secondary prevention of sudden cardiac death [1]. Recently, a report was published about a previously described complication of the electrode, in which a defect of the so-called Sense-B component is reported in a few affected patients. The defect of this component of the electrode leads to electrode noise and subsequent inadequate shocks. The cause of the defect and the incidence are currently unknown [2]. The manufacturer Boston Scientific has issued a warning and advisory [3].

    In addition to this advisory regarding the electrode of the S-ICD, there is also an active warning from the manufacturer regarding the possible premature exhaustion of the S-ICD battery [4] and [5]. This is caused by an error in the manufacturing process of approximately 40,000 devices produced in 2018. The manufacturer estimates the incidence of premature battery exhaustion to be 4-15% within 5 years. Independent data on the incidence of premature exhaustion of these devices were initially scarce. We conducted a retrospective data query in 2021 to capture the incidence of battery exhaustion at that time. The incidence was 3.7% after 5 years. [6] The average follow-up time was only 3 years. The incidence of premature exhaustion increased significantly after 3 years, so data with a longer follow-up period is urgently needed.

    Given that these data already show that the incidence of premature exhaustion increases significantly after 3 years and the observation period in the retrospective data was on average slightly under 3 years, a further query of the existing clinical data on the battery as part of this register is also planned. This would allow for a more accurate estimate of the risk of premature battery depletion.

    Literature

    1. Knops et al. N Engl J Med 2020; 383:526-536, DOI:10.1056/NEJMoa1915932

    2. Haeberlin A, et al. Sense-B-noise: an enigmatic cause for inappropriate shocks in subcutaneous implantable cardioverter defibrillators. Europace. 2022 Nov 10:euac202. doi: 10.1093/europace/euac202. Epub ahead of print. PMID: 36353759.

    3. https://www.bostonscientific.com/content/dam/bostonscientific/quality/dlt/reg-code-228/2 020Dec_BSC_EmblemElectrode3501_PhysLtr_Final.pdf

    4. Quast et al. J Cardiovasc Electrophysiol, 2018 Jul;29(7):1010-1016. doi: 10.1111/jce.13498

    5. https://www.bfarm.de/SharedDocs/Kundeninfos/EN/01/2020/20857-20_kundeninfo_en.pdf?__blob =publicationFile&v=1

    6. Lüker, J., Strik, M., Andrade, J.G. et al. Incidence of premature battery depletion in subcutaneous cardioverter-defibrillator patients: insights from a multicenter registry. J Interv Card Electrophysiol (2023). https://doi.org/10.1007/s10840-023-01468-1

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Multicenter Registry for S-ICD Electrodes
    Anticipated Study Start Date :
    Mar 1, 2023
    Anticipated Primary Completion Date :
    Oct 1, 2023
    Anticipated Study Completion Date :
    Oct 2, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Sense B Electrode Failure [3 months to 70 months after device insertion]

      Incidence of the Sense B Electrode Failure of the S-ICD Lead.

    Secondary Outcome Measures

    1. Premature Battery Depletion [3 months to 70 months after device insertion]

      Incidence of battery depletion of the S-ICD generator after insertion.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    8 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    status post S-ICD implantation

    Exclusion Criteria:

    no available follow-up data

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Cologne Cologne NRW Germany 50937

    Sponsors and Collaborators

    • Universitätsklinikum Köln

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Universitätsklinikum Köln
    ClinicalTrials.gov Identifier:
    NCT05713708
    Other Study ID Numbers:
    • SICDLEAD
    First Posted:
    Feb 6, 2023
    Last Update Posted:
    Feb 6, 2023
    Last Verified:
    Jan 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Universitätsklinikum Köln
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 6, 2023